Back to top
more

Dr. Reddys Laboratories (RDY)

(Delayed Data from NYSE)

$13.33 USD

13.33
1,434,801

-0.34 (-2.49%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $13.36 +0.03 (0.23%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (161 out of 246)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

New Strong Sell Stocks for November 15th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Zacks Equity Research

New Strong Sell Stocks for November 13th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Zacks Equity Research

New Strong Sell Stocks for November 11th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Zacks Equity Research

Dr. Reddy's (RDY) Q2 Earnings and Revenues Increase Y/Y

by Zacks Equity Research

Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2020.

Zacks Equity Research

Mylan (MYL) to Pay $30M to Settle SEC Charges for EpiPen

by Zacks Equity Research

Mylan (MYL) sinks after the SEC charges it for misclassification of EpiPen.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Dr. Reddy's, WNS and Azure Power

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Dr. Reddy's, WNS and Azure Power

Zacks Equity Research

BridgeBio Pharma (BBIO) Jumps: Stock Rises 7.1%

by Zacks Equity Research

BridgeBio Pharma (BBIO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Zacks Equity Research

Foamix Initiates Phase II Study on Acne Combination Foam

by Zacks Equity Research

Foamix (FOMX) enrolls first patient in phase II study on its topical combination foam, FCD105, for the treatment of moderate-to-severe acne vulgaris.

Tirthankar Chakraborty headshot

Is it Apt to Foray Into the Indian Stock Market?: An Analysis

by Tirthankar Chakraborty

The government of India unveils an array of concessions to spur the economy. This in turn will slash most corporate taxes to 22% while new manufacturers will pay even a lower corporate tax rate of 15%.

Zacks Equity Research

J&J's Prostate Cancer Drug Gets FDA Nod for Expanded Use

by Zacks Equity Research

J&J's (JNJ) sNDA seeking approval of Erleada for metastatic castration-sensitive prostate cancer is based on data from TITAN study.

Zacks Equity Research

Zynerba Releases Data on Epilepsy Candidate, Stock Down

by Zacks Equity Research

Zynerba (ZYNE) announces positive top-line results from the BELIEVE 1 study evaluating the efficacy and safety of Zygel in a heterogeneous group of rare and ultra-rare epilepsies.

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for September 17th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 17th

Zacks Equity Research

What Makes Doctor Reddy's (RDY) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Doctor Reddy's (RDY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Apple, Harmony Gold, NRG, Ryman Hospitality and Dr. Reddy's

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Apple, Harmony Gold, NRG, Ryman Hospitality and Dr. Reddy's

Sweta Killa headshot

Top Stories of August Worth Watching in September

by Sweta Killa

We discuss some of the events that dominated the headlines in August and will be worth watching this month.

Zacks Equity Research

5 Stocks From the Best Performing Sectors in Q2

by Zacks Equity Research

We have shortlisted solid stocks from the top-performing sectors in Q2 that should make a great addition to your portfolio.

Sweta Killa headshot

5 Stock-Picking Strategies to Counter Market Turbulence

by Sweta Killa

We have highlighted some stock-picking ideas from the top-ranked cohort that could prove extremely beneficial for investors by reducing the risk of a downside.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for August 1st

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday

Zacks Equity Research

Dr. Reddy's (RDY) Q1 Earnings and Revenues Increase Y/Y

by Zacks Equity Research

Dr. Reddy's (RDY) earnings and sales increase year over year in the first quarter of fiscal 2020.

Zacks Equity Research

Dr. Reddy's Inks Deal to Sell Neurology Branded Products

by Zacks Equity Research

Dr. Reddy's (RDY) announced that it has entered a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC to sell its neurology branded products.

Zacks Equity Research

Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug

by Zacks Equity Research

Dr. Reddy's (RDY) reports positive top-line results from the phase IIb study on PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.

Zacks Equity Research

BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady

by Zacks Equity Research

BioMarin's (BMRN) Vimizim gains an NMPA nod in China for addressing patients suffering Morquio A syndrome, an ultra-rare genetic condition.

Zacks Equity Research

New Strong Sell Stocks for May 22nd

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

Zacks Equity Research

Dr. Reddy's (RDY) Q4 Earnings Up Y/Y, Revenues Top Estimates

by Zacks Equity Research

Dr. Reddy's (RDY) fourth-quarter earnings and sales increase year over year.

Zacks Equity Research

Dr. Reddy's (RDY) Earnings Rise in Q4, Revenues Beat

by Zacks Equity Research

Dr. Reddy's earnings and sales increase year over year in the fourth quarter of fiscal 2019.